1-6 of 6
Emily K Jeng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, MS, Emily K Jeng, Sarah Alter, PhD, Peter R Rhode, PhD, John H Lee, MD, Gaurav Nayyar, MD PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell Cairo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3697.
https://doi.org/10.1182/blood-2018-99-117683
Published: 2018
Journal Articles

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Clinical Trials & Observations
Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott, Peter Westervelt, Michael R. Verneris, John E. Wagner, Daniel J. Weisdorf, Bruce R. Blazar, Celalettin Ustun, Todd E. DeFor, Sithara Vivek, Lindsey Peck, John F. DiPersio, Amanda F. Cashen, Rachel Kyllo, Amy Musiek, András Schaffer, Milan J. Anadkat, Ilana Rosman, Daniel Miller, Jack O. Egan, Emily K. Jeng, Amy Rock, Hing C. Wong, Todd A. Fehniger, Jeffrey S. Miller
Journal: Blood
Blood (2018) 131 (23): 2515–2527.
https://doi.org/10.1182/blood-2017-12-823757
Published: 2018
Includes: Supplemental data
Journal Articles

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Rizwan Romee, MD, Sarah Cooley, MD, Melissa Berrien-Elliott, PhD, Peter Westervelt, MDPhD, Michael R Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John F DiPersio, MD PhD, Amanda F. Cashen, MD, Emily K Jeng, Amy Rock, Hing C Wong, PhD, Todd A. Fehniger, MDPhD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 274.
https://doi.org/10.1182/blood.V130.Suppl_1.274.274
Published: 2017
Journal Articles

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, BS, Sarah Alter, PhD, Emily K Jeng, Peter R Rhode, PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3587.
https://doi.org/10.1182/blood.V130.Suppl_1.3587.3587
Published: 2017
Journal Articles

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Tarun K. Garg, PhD, Katie Stone, BS, Amy Greenway, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Hing C Wong, PhD, Emily K Jeng, Niraj Shrestha, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits van Rhee, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5452.
https://doi.org/10.1182/blood.V130.Suppl_1.5452.5452
Published: 2017
Journal Articles

The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody

Maximillian Rosario, MDPhD, Bai Liu, Lin Kong, Stephanie E Schneider, Emily K Jeng, Peter R Rhode, PhD, Hing Wong, PhD, Todd A Fehniger, MDPhD
Journal: Blood
Blood (2014) 124 (21): 807.
https://doi.org/10.1182/blood.V124.21.807.807
Published: 2014